116 related articles for article (PubMed ID: 11365540)
21. Remune trial stopped.
Vazquez E
Posit Aware; 1999; 10(4):29. PubMed ID: 11366802
[TBL] [Abstract][Full Text] [Related]
22. Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies.
Angel JB
AIDS Read; 2001 Apr; 11(4):209-21. PubMed ID: 11392678
[TBL] [Abstract][Full Text] [Related]
23. A potent weapon in the battle against HIV: your own immune system.
Proj Inf Perspect; 2002 Mar; (34):14-6. PubMed ID: 12038300
[TBL] [Abstract][Full Text] [Related]
24. Immune based therapy update.
Proj Inf Perspect; 1998 Sep; (25):17-9. PubMed ID: 11365845
[TBL] [Abstract][Full Text] [Related]
25. Does the HIV-1deltakURNe vaccine strain hold the key to curbing HIV infection? An interview with Ronald Desrosiers, PhD.
Desrosiers R
J Int Assoc Physicians AIDS Care; 1998 Mar; 4(3):45-6. PubMed ID: 11365180
[TBL] [Abstract][Full Text] [Related]
26. Immune-based therapies in brief.
Proj Inf Perspect; 2000 Mar; (29):19-20. PubMed ID: 12772669
[TBL] [Abstract][Full Text] [Related]
27. Remune bites the dust...again.
Vázquez E
Posit Aware; 2001; 12(5):21. PubMed ID: 11688479
[No Abstract] [Full Text] [Related]
28. Salk therapy begins.
Posit Aware; 1996; 7(3):7. PubMed ID: 11363429
[TBL] [Abstract][Full Text] [Related]
29. FDA advisory committees meet January 26 on Salk HIV-1 immunogen.
AIDS Treat News; 1995 Jan; (No 214):1-2. PubMed ID: 11362184
[TBL] [Abstract][Full Text] [Related]
30. [Vaccines against HIV].
Holm-Hansen C
Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
[TBL] [Abstract][Full Text] [Related]
31. Improving HIV-specific immune responses in HIV-infected patients.
Hardy GA; Imami N; Gotch FM
J HIV Ther; 2002 May; 7(2):40-5. PubMed ID: 12553687
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic vaccines for chronic infections.
Autran B; Carcelain G; Combadiere B; Debre P
Science; 2004 Jul; 305(5681):205-8. PubMed ID: 15247470
[TBL] [Abstract][Full Text] [Related]
33. Remune trials recruiting.
PI Perspect; 1996 Sep; (No 19):17. PubMed ID: 11363901
[TBL] [Abstract][Full Text] [Related]
34. Restoring HIV-specific immunity.
James JS
AIDS Treat News; 1999 Feb; (No 312):2-6. PubMed ID: 11366200
[TBL] [Abstract][Full Text] [Related]
35. An interview with Simon Wain-Hobson, PhD. Interview by Mark Mascolini.
Wain-Hobson S
J Int Assoc Physicians AIDS Care; 1995 May; 1(4):8-13. PubMed ID: 11362509
[TBL] [Abstract][Full Text] [Related]
36. [HIV/AIDS vaccines: heading for new vaccine approaches?].
Girard MP
Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
[TBL] [Abstract][Full Text] [Related]
37. Rebuilding the immune system.
Averitt D
WORLD; 1999 Apr; (No 96):1-2. PubMed ID: 11366944
[TBL] [Abstract][Full Text] [Related]
38. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.
Bhardwaj N; Walker BD
Nat Med; 2003 Jan; 9(1):13-4. PubMed ID: 12514710
[No Abstract] [Full Text] [Related]
40. Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice.
Da'Dara AA; Lautsch N; Dudek T; Novitsky V; Lee TH; Essex M; Harn DA
Vaccine; 2006 Jun; 24(24):5211-9. PubMed ID: 16675073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
